NCT05300828View on ClinicalTrials.gov

Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer

CompletedOBSERVATIONAL
Enrollment

600

Participants

Timeline

Start Date

October 19, 2015

Primary Completion Date

April 30, 2022

Study Completion Date

December 31, 2022

Conditions
Ovarian Cancer
Interventions
DRUG

Genexl PM

Every three weeks, after intravenous infusion of 260 mg/m2 for 3 hours, followed by carboplatin AUC 5 for 3 hours.

Trial Locations (1)

Unknown

Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, Ajou University School of Medicine, Suwon

All Listed Sponsors
collaborator

Samyang Biopharmaceuticals Corporation

INDUSTRY

lead

Seoul National University Hospital

OTHER

NCT05300828 - Safety of Genexol PM and Carboplatin as First-line Therapy in Ovarian Cancer | Biotech Hunter | Biotech Hunter